Cargando…
Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
We aimed to evaluate ERG and SOX9 as potential biomarkers of docetaxel response in metastatic castration-resistant prostate cancer (mCRPC) patients. Seventy-one mCRPC patients were evaluated. Tissue microarrays were constructed and immunohistochemistry was performed. Treatment response was assessed...
Autores principales: | Song, Wan, Kwon, Ghee Young, Kim, Jeong Hoon, Lim, Joung Eun, Jeon, Hwang Gyun, Il Seo, Seong, Jeon, Seong Soo, Choi, Han Yong, Jeong, Byong Chang, Lee, Hyun Moo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347800/ https://www.ncbi.nlm.nih.gov/pubmed/27863438 http://dx.doi.org/10.18632/oncotarget.13407 |
Ejemplares similares
-
A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
por: Kim, Hae Su, et al.
Publicado: (2017) -
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
por: Byeon, Seonggyu, et al.
Publicado: (2021) -
A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019) -
Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
por: Byeon, Seonggyu, et al.
Publicado: (2020) -
Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
por: Yu, Jiwoong, et al.
Publicado: (2021)